about
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccinationMorbillivirus Experimental Animal Models: Measles Virus Pathogenesis Insights from Canine Distemper VirusNew vaccine design based on defective genomes that combines features of attenuated and inactivated vaccinesMeasles virus selectively blind to signaling lymphocytic activation molecule (SLAM; CD150) is attenuated and induces strong adaptive immune responses in rhesus monkeys.Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein.An immune competent mouse model for the characterization of recombinant measles vaccines.Tunable and reversible drug control of protein production via a self-excising degron.Expression of immunomodulatory neutrophil-activating protein of Helicobacter pylori enhances the antitumor activity of oncolytic measles virus.A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge.Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.Broadly neutralizing immune responses against hepatitis C virus induced by vectored measles viruses and a recombinant envelope protein boosterRecombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma.Replicating and non-replicating viral vectors for vaccine developmentThe successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection.Measles vaccination: new strategies and formulations.Sequence and immunogenicity of a clinically approved novel measles virus vaccine vector.Measles virus expressed Helicobacter pylori neutrophil-activating protein significantly enhances the immunogenicity of poor immunogens.Applications and challenges of multivalent recombinant vaccines.RNA-based viral vectors.Vaccine platform recombinant measles virus.Multivalent and Multipathogen Viral Vector Vaccines.Novel viral vectors in infectious diseases.Development of Recombinant Measles Virus-Based Vaccines.Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.Measles virus.Relevance of a pre-existing measles immunity prior immunization with a recombinant measles virus vector.Replicating adenovirus vector prime/protein boost strategies for HIV vaccine developmentNew Vaccine Technologies to Combat Outbreak Situations
P2860
Q26700080-E8EE27E4-230B-4CA9-869E-A2B89C38E200Q28069402-18597B2A-D9B2-4FF8-B5E9-BF6D4EF27FEDQ33573531-48B86574-5468-42D6-85B6-AA7B541921A0Q33725565-3AFDC59C-B29F-4DE3-B2FE-43E354FB34C8Q35096934-A9FA9B5F-975B-4891-A956-7B86AEEC45CDQ35887095-F55912AE-EF6D-4187-914A-ED3C185D8FEDQ35977821-1C984D52-D4D4-4216-942E-93EBD0C8C500Q36014057-077B1463-ADB6-409D-A0EB-D7BA19D82007Q36099144-99E7C71A-8BA4-438B-8818-1F79FB9B0E29Q36183321-B9F7A9EC-92C4-4834-952A-086BF8AC4360Q36363203-46F9A797-3C25-457A-AC97-5D5E169B392DQ36366466-9E1A34C1-B076-4709-B580-E0F67BCBFFB4Q36464587-498E092B-8EB7-4348-813F-BDD2285B3151Q37135489-54F64193-41D2-4071-8F5C-13C7E2C70955Q37290110-9C911784-D869-41AB-A6AB-CA027141FB4BQ37478331-70F47BD7-1287-4EDF-B4B4-E1098CB37290Q37520259-C8497A6D-E57B-4F84-A6DA-7AD65B6C2A29Q38068270-ADF555DA-9D16-4FED-A9EB-23E7FDA4F759Q38266413-73D14FE6-C15C-4B56-B341-DADED8E78A7FQ38657271-58DBF9FE-A5E6-4CB6-883C-9007202A5D64Q38830323-77FE2273-F565-4C5D-A7F0-928AA0C4E525Q40059020-4DF69A5B-C2D4-4CEE-A8E3-43E210BE0B94Q40259612-8B2D7607-EA4F-4122-AC3E-53C522B4CD7CQ41557807-BF69A65F-42FD-4858-A843-CF21EDFB8F0BQ41612319-7E33B9AF-0EFD-430C-8F6C-2A845588DFCDQ41871491-08E9EB31-D8B2-4BC4-9E9A-2B34B5E855CCQ56993265-2DFCC9D4-B3EA-42C3-A4E5-C5EC3BE709D2Q57072744-06148357-DCAA-4B95-BD79-4C055CFE721F
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Attenuated measles virus as a vaccine vector.
@en
type
label
Attenuated measles virus as a vaccine vector.
@en
prefLabel
Attenuated measles virus as a vaccine vector.
@en
P2093
P2860
P921
P1433
P1476
Attenuated measles virus as a vaccine vector.
@en
P2093
Armando Zuniga
Hussein Y Naim
Jean Francois Viret
Jovan Pavlovic
Lars Hangartner
Martin A Billeter
Matthias Liniger
Michael Caballero
Peter Wild
Reinhard Glueck
P2860
P304
P356
10.1016/J.VACCINE.2007.01.064
P407
P577
2007-02-02T00:00:00Z